Employees must meet all eligibility requirements in order to qualify. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. The 2022 non-GAAP EPS guidance is further explained under Use of Non-GAAP Financial Information. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. 0000011095 00000 n Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023, Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share, Expected to be Accretive to Non-GAAP Earnings Per Share beginning in 2025. Learn more! The Office of Corporate Conduct is a resource for any employee to confidentially and anonymously report their concerns or raise questions. Add to iCalendar. 0000010800 00000 n Worldwide revenues are expected to be approximately $47 billion, representing an increase in the low-single digits. The sale was disclosed in a legal filing Bristol Myers Squibb announced on Feb. 5 that the US Food and Drug Administration (FDA) has approved its lymphoma drug, Breyanzi, a CAR-T (chimeric antigen receptor T-cell) therapy for the treatment of adult patients suffering from relapsed or refractory large B-cell lymphoma. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. xref hb```b``{Ab,GU\r``8e/Gu sMJM ;xxDFD>]/=nxoEA2nlt2Tr2\+lcGC=!Rq(t=-SPMHj>Ytv@! We know its not easy to make a difference, so we make sure each employee feels empowered and motivated in their efforts to do so. Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. Tuesday, November 16, 2021. (Reuters) - A judge in Hawaii on Monday ordered Bristol-Myers Squibb (NYSE: BMY) Co and Sanofi (NASDAQ: SNY) SA Following the sale, the senior vice president now directly owns 16,243 shares in the company, valued at $1,042,963.03. 813 0 obj Home; Our Services; About us; Blog; Contact It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. We routinely post important information for investors on our website, BMS.com, in the Investors section. Bristol Myers Squibb expects to finance the acquisition with cash on hand. Play. 0000012839 00000 n Available to US-based employeesChange location. , bristol myers squibb holiday calendar 2021 2021, bristol myers squibb holiday calendar 2021, Cigna Behavioral Health Provider Phone Number, A Person Will Become Responsible If He/she Is Brainly, Classes Offered At Gateway Community College. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. 813 55 Share; Facebook; Twitter; LinkedIn . Access thousands of interactive online resources to gain the skills you need, when you need them. In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, the company and Turning Point Therapeutics file annual, quarterly and special reports, proxy statements and other information with the SEC. trailer 33 days holiday (inc. bank holidays) - prorated - with the option to buy/sell 5 additional days ; These documents will be available at no charge on the SECs website at www.sec.gov. 0000003660 00000 n A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. 0000004547 00000 n Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year? Learn about Bristol Myers Squibb Paid Holidays, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. LICENSE AGREEMENT. Expects low- to mid-single digit revenue CAGR and low double-digit revenue CAGR for our Continuing Business, Expects to maintain low- to mid-40s percent non-GAAP operating margin, Expects significant free cash flow generation of $45-$50 billion dollars from 2022-2024. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Bristol-Myers Squibb Company (BMY) NYSE - Nasdaq Real Time Price. 0000014201 00000 n No additional data or studies have been requested. 0000013014 00000 n Learn about joining our global team! Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. Your response will be removed from the review this cannot be undone. Your response will be removed from the review this cannot be undone. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. Holiday Calendar; Earnings Calendar; A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. ET on February 18, 2022 by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 2150568. endstream 0000015083 00000 n Non-GAAP EPS . 0000003062 00000 n Our Continuing Business, which represents in-line products and new product portfolio, is expected to grow in the low-double digits and contribute approximately $36.5 billion in 2022. Warnings Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug. Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer. The company reported net earnings attributable to Bristol Myers Squibb of $2.4 billion, or $1.07 per share, in the fourth quarter, compared to net loss of $10.0 billion, or $(4.45) per share, for the same period a year ago. Catalyst and Talent Accelerator: unique programs designed to accelerate the leadership potential of high performing individuals to drive global innovation and business results. Tuition reimbursement is available to eligible employees who, through their own initiation and desire for development, participate in accredited educational programs that their manager deems will be mutually beneficial to BMS and the employee. Cautionary Statement Regarding Forward-Looking Statements. Bristol Myers Squibb is also reaffirming its previously communicated 2020-2025 long-term targets: This financial guidance excludes the impact of any potential future strategic acquisitions and divestitures as well as any specified items as discussed under Use of Non-GAAP Financial Information. There is no reliable or reasonably estimable comparable GAAP measures for this non-GAAP financial guidance. The recognition is a testament to our commitment to transform patients lives through science. By 1943, Squibb operated the largest penicillin production plant in the world in New Brunswick, New Jersey. 0000008372 00000 n 0000003811 00000 n "The first of the new aircraft will enter service in late-2023, with the bulk to . Both GAAP and non-GAAP guidance assume current exchange rates. In addition, the compounds described in this communication are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. )yJP The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. Gross margin increased from 73.7% to 80.3% in the quarter primarily due to an impairment charge related to marketed product rights in the same period a year ago and lower unwinding of inventory purchase price accounting adjustments. 0000011978 00000 n With your consent, we may also use third party cookies to analyze your usage of the website. Our financial strength, dedicated workforce and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation and position the company for sustained growth., $ amounts in millions, except per share amounts. Usually give off For the year end holidays too! U.S. revenues increased 11% to $7.5 billion in the quarter. Turning Point Therapeutics When adjusted for foreign exchange impact, international revenues increased 7%. Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. The news made me sad as I found her career path quite inspiring Mar 02, 2023 (Prime PR Wire via Comtex) -- This "Organ Transplant Rejection Medication Market" study analyses the market and offers thorough insights to help. bristol myers squibb holiday schedule 2021. par | Juin 16, 2022 | park hyung sik and park seo joon are brothers | hamiltonian path greedy algorithm | Juin 16, 2022 | park hyung sik and park seo joon are brothers | hamiltonian path greedy algorithm Bristol Myers Squibb (NYSE: BMY) looks very attractive at current levels of $63, as The Max Foundation and Bristol-Myers Squibb are teamed up to help even more people around the globe face cancer with dignity and hope. Research and development expenses decreased 30% to $2.6 billion in the quarter. NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company's pipeline that further progressed the company's portfolio renewal. 0000010676 00000 n Ensured work schedule for each day was achieved and liaised with all key personnel as . There will be a conference call on February 4, 2022 at 8 a.m. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the companys business nor reflect the companys underlying business performance. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer will answer questions about the company at 5 p.m. Bristol-Myers Squibb's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B. We demonstrate this inclusion within our eight employee-led People and Business Resource Groups, which offer all colleagues the opportunity to use their unique skills in support of our company, our communities and our patients around the world. Usually give off For the year end holidays too! Add to Apple Calendar. With Bristol Myers Squibbs leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world., Financial Details and 2022 Financial Guidance. 2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. Israel holiday schedule. There are no upcoming events. We incorporate security and human rights in our assessment of countries when determining where to locate operating facilities. 0000043107 00000 n Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy. Japan's Ministry of Health, Labour and Welfare also accepted the NDA for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. schedule conferences . Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. A dds details on agreement, background. All comparisons are made versus the same period in 2020 unless otherwise stated. Security personnel receive training to ensure compliance with legal requirements and respect for human rights. . BMY: Get the latest Bristol-Myers Squibb stock price and detailed information including BMY news, historical charts and realtime prices. Jun 11, 2021 5:45PM EDT. Aug 2010 - Present12 years 8 months. For your convenience, specialized Bristol Myers Squibb representatives are available by phone or email to help you with your medical, technical, or general inquiries. (PDF). Sales from key loss of exclusivity (LOE) brands, which represent. Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the companys pipeline that further progressed the companys portfolio renewal. Shareholders who. 0000002307 00000 n they used to have flexible schedules- though that is unfortunately being phased out. In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, statements relating to goals, plans and projections regarding the companys current and projected financial position, results of operations, market position, product development, share repurchase program and business strategy. Cautionary Statement Regarding Forward-Looking Statements. We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. Monthly calendar; Candle-lighting times only . Choosing Your Medical Plan. #BMSCareers. Available to US-based employeesChange location, Comparable to many others in the same league. Goldman Sachs & Co. LLC is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley LLP is serving as legal counsel. 0000007516 00000 n Bristol-Myers Squibb has a 1 year low of $54.07 and a 1 year high of $67.16. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients., Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. Written by Zacks Equity Research for Zacks ->. The extension will allow sufficient time to review information pertaining to updates of the proposed Risk Evaluation Mitigation Strategy (REMS). And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. 0000193438 00000 n Media: media@bms.com Minor Holidays . 0000115702 00000 n An effective tax rate of approximately 24% for GAAP and approximately 16.5% for non-GAAP. This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point Therapeutics by the company and the development and commercialization of certain biological compounds. The tender offer described in this communication has not yet commenced. Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. I am proud of how our company performed in 2021, helping more patients across our therapeutic areas, while achieving 9% revenue and 17% non-GAAP EPS growth, respectively, said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. bristol myers squibb Dublin, Ireland . 867 0 obj ET on April 29, 2021 Bristol-Myers Squibb (NYSE:BMY) SVP Adam Dubow sold 3,119 shares of the business's stock in a transaction dated Wednesday, May 5th. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. By Tina Bellon and Nate Raymond. We believe that success of our science is measured by the lives we touch. The FDA has accepted the NDA and the EMA has validated the Marketing Authorization Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. . Mily spoke to S&P Global Market Intelligence ahead of the 2021 J.P. Morgan Healthcare Conference beginning Jan. 11 about the company's plans for future M&A and partnerships. The case is UMB Bank NA v Bristol-Myers Squibb (NYSE: BMY) Co et al, U.S. District Court, Southern District of New York, No. I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. Media and Investor Relations: ir@tptherapeutics.com, Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. 0000005488 00000 n Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. This information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. 3 floating holidays. Supervised Warehouse staff. TOKYO & NEW YORK, Jun 17, 2021--(BUSINESS WIRE)--Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). In addition to the items discussed above, the results in the same period a year ago included an IPR&D charge related to the MyoKardia asset acquisition of $11.4 billion and the impact of fair value adjustments on equity investments and contingent value rights in both periods. A REMS program was included in the initial application for mavacamten. Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. 0000043468 00000 n Every year, key managers and executives are required to certify that they have read, understand, are in compliance with, and will continue to comply with our Standards of Business Conduct and Ethics. Elizabeth Mily joined Bristol Myers Squibb Co. as executive vice president of strategy and business development in March 2020 after 27 years in investment banking. During a conference call at 9 a.m. Shares of Bristol Myers Squibb Co. BMY, +0.36% shed 2.1% in premarket trading Thursday, after the drug maker reported a first-quarter profit that BMY AGEN. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. (. Virtual Benefits Fair. Youll find valuable developmental opportunities to help connect you to your passion and drive your career forward. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. Top 40%. For your convenience, we provide daily services that save you time. Month List Download. ET on February 4 through 11:30 a.m. Print. There's been plenty of good news for Bristol Myers Squibb (BMY 0.13%) . Top 50%. Diaspora holiday schedule. 0 0000011122 00000 n Amortization of acquired intangible assets decreased 4% to $2.4 billion in the quarter primarily due to an extended marketed product rights exclusivity period. 0000013257 00000 n 0000008533 00000 n On Nov. 12, 2021, the Commission announced that it has approved certain modifications to Bristol Meyers Squibb's divestiture agreements. 0000004898 00000 n Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. We are committed to following all laws regarding child labor, forced labor and freedom of association. Bristol-Myers Squibb expanded its collaboration to help The Max Foundation reach 45% The biopharmaceutical company reported $1.74 earnings per share for the quarter, missing analysts' consensus estimates of $1.82 by ($0.08). Bristol-Myers is Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: 21-04897. Jewish Calendar 2021 Tuusula, Uusimaa, Finland. 0000012578 00000 n The basis for our security efforts is to protect our employees, operations and intellectual property. A cash dividend payment of $0.49 per share is scheduled to be paid on August 02, 2021. Past events. Our people Our global workforce is made up of over 26,000 passionate people who, in 2021, helped Pandora record the highest earnings to date, led by a refreshed long-term growth strategy. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. Find out why possibility lives at Bristol Myers Squibb, We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues, We pursue disruptive and bold solutions for patients, We move together with speed and quality because patients are waiting, Our dedication to learning and excellence helps us to deliver exceptional results, We all own BMS success and strive to be transparent and deliver on our commitments, We embrace diversity and foster an environment where we can all work together at our full potential. Materials on this website may contain information about the Companys future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Listen to Webcast. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com . Bristol-Myers Squibb BMY | stock $69.02 0.09% $147 B 3.31% $2.28 - Ratings - BMY Dividend Safety A+ 16 years of consecutive dividend increase. The stock was sold at an average price of $64.21, for a total transaction of $200,270.99. though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow." Senior Research Investigator salaries ($93k), Research Investigator II salaries ($108k), Associate Research Scientist I salaries ($70k), Senior Research Investigator II salaries ($132k), Associate Research Scientist II salaries ($77k). Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Please speak with your recruiter for more information. (. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. We claim: 1. June 08, 2022 06:59 AM Eastern Daylight Time. <> 0000003993 00000 n Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. 0000192879 00000 n The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.1 billion, or $1.83 per share, in the fourth quarter, compared to non-GAAP net earnings of $3.3 billion, or $1.46 per share, for the same period a year ago. (EPS) for full-year 2021 between $3.18 and $3.38, up from its previous forecast of a range of $3.12 to $3.32. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted.